Skip to Main Content

Paper Details

Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial.
Clin Cancer Res
24
2022
Author NameAffiliation
Shekhar GhamandeCancer Center, Medical College of Georgia, Augusta University
  • 1 - 1

Datasets

Release 1.2